Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $165,327.36 in Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) insider Jennifer Michaelson sold 11,742 shares of Cullinan Therapeutics stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $14.08, for a total transaction of $165,327.36. Following the sale, the insider directly owned 181,977 shares in the company, valued at $2,562,236.16. This trade represents a 6.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jennifer Michaelson also recently made the following trade(s):

• On Tuesday, February 24th, Jennifer Michaelson sold 3,601 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $14.47, for a total transaction of $52,106.47.
• On Monday, February 23rd, Jennifer Michaelson sold 1,752 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $13.99, for a total transaction of $24,510.48.
• On Thursday, February 12th, Jennifer Michaelson sold 416 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $5,004.48.
• On Thursday, January 22nd, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.30, for a total value of $49,200.00.
• On Friday, December 19th, Jennifer Michaelson sold 1,345 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $10.01, for a total value of $13,463.45.
• On Thursday, December 18th, Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $9.67, for a total value of $28,023.66.
• On Monday, December 15th, Jennifer Michaelson sold 995 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $11.90, for a total value of $11,840.50.
• On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.38, for a total value of $26,592.24.

Cullinan Therapeutics Price Performance

NASDAQ:CGEM opened at $14.36 on Thursday. The firm’s 50 day simple moving average is $11.50 and its 200 day simple moving average is $9.31. Cullinan Therapeutics, Inc. has a one year low of $5.68 and a one year high of $14.56. The company has a market cap of $848.39 million, a PE ratio of -4.34 and a beta of -0.09.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on CGEM shares. Zacks Research downgraded Cullinan Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. HC Wainwright upped their price target on Cullinan Therapeutics from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. New Street Research set a $26.00 price objective on Cullinan Therapeutics in a research report on Thursday, November 20th. Wedbush upped their target price on Cullinan Therapeutics from $25.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Finally, Morgan Stanley reissued an “overweight” rating and set a $30.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, January 8th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.33.

Key Stories Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Analysts remain bullish and have pushed price targets higher, citing Cullinan’s T‑cell engager pipeline (notably CLN‑049) and strong cash runway; multiple firms maintain Buy/Outperform ratings, supporting upside expectations. Seeking Alpha: Thesis Strengthening For This T-Cell Engager Specialist
• Positive Sentiment: Cullinan announced management will participate in upcoming investor conferences (CEO Nadim Ahmed and CMO/other executives presenting), which could provide fresh visibility, program updates and near‑term catalysts. GlobeNewswire: Investor Conferences
• Neutral Sentiment: Technical/fundamental context — the stock is trading above its 50‑ and 200‑day moving averages and near its 52‑week high, reflecting momentum; market cap remains in the ~$800M range. MarketBeat: CGEM profile
• Neutral Sentiment: Short interest data in recent reports show effectively zero shares reported — likely a reporting artifact; does not indicate meaningful short pressure based on available figures. SEC / Filings (example)
• Negative Sentiment: Insider selling — several insiders (CEO Nadim Ahmed, CFO Mary Kay Fenton, Jacquelyn Sumer, Jennifer Michaelson, Jeffrey A. Jones and others) disclosed sales over Feb. 20–24, trimming low‑single‑digit percentages of their holdings and totaling tens of thousands of shares; simultaneous insider sales can create short‑term downward pressure. CEO Filing (example)
• Negative Sentiment: Multiple media and data aggregators are reporting the insider transactions together, increasing visibility of the sales to the market and potentially amplifying near‑term selling sentiment. InsiderTrades summary

Hedge Funds Weigh In On Cullinan Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Affinity Asset Advisors LLC increased its stake in shares of Cullinan Therapeutics by 632.4% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,932,106 shares of the company’s stock valued at $19,997,000 after acquiring an additional 1,668,289 shares in the last quarter. Lynx1 Capital Management LP grew its holdings in Cullinan Therapeutics by 31.0% in the third quarter. Lynx1 Capital Management LP now owns 5,766,090 shares of the company’s stock worth $34,193,000 after purchasing an additional 1,365,248 shares during the period. Boothbay Fund Management LLC acquired a new stake in Cullinan Therapeutics in the fourth quarter worth $12,803,000. State Street Corp increased its stake in Cullinan Therapeutics by 31.0% in the fourth quarter. State Street Corp now owns 2,197,338 shares of the company’s stock valued at $22,742,000 after purchasing an additional 520,024 shares in the last quarter. Finally, Caption Management LLC raised its holdings in shares of Cullinan Therapeutics by 107.0% during the third quarter. Caption Management LLC now owns 28,389 shares of the company’s stock valued at $168,000 after purchasing an additional 435,062 shares during the period. 86.31% of the stock is currently owned by institutional investors.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.